Published TCIMAIL newest issue No.196
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 212142-18-2 | Product Number: V0198
Vatalanib Succinate
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine Succinate
Product Documents:
| Size | Unit Price | Belgium | Japan* | Quantity |
|---|---|---|---|---|
| 25MG |
215,00 €
|
Contact Us | 20 |
|
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
| Product Number | V0198 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__2__0H__1__5ClN__4·C__4H__6O__4 = 464.91 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Frozen (-20°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Air Sensitive,Heat Sensitive |
| CAS RN | 212142-18-2 |
| Reaxys Registry Number | 14123653 |
Specifications
| Appearance | White to Light yellow to Light orange powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
| NMR | confirm to structure |
Properties (reference)
GHS
Related Laws:
Transport Information:
Application
Vatalanib Succinate: A Specific Inhibitor of VEGF Receptor Tyrosine Kinases
Vascular endothelial growth factor (VEGF) is one of the major factors involved in tumor angiogenesis and has become an important target for cancer therapy. Vatalanib succinate (PTK787 /ZK 222584) is a specific inhibitor of all three VEGF receptor (VEGF-R1, VEGF-R2 and VEGF-R3) tyrosine kinases, which shows antitumor and anti-angiogenic activity in cancer cells. (The product is for research use only.)
References
- PTK787 /ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
- Effects of PTK787 /ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model
- PTK787 /ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging
- Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787 /ZK 222584 (a review)
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.